Challenges in the diagnosis of Parkinson’s disease

By Eduardo Tolosa, Alicia Garrido, Sonja W. Scholz, W. Poewe. Lancet Neurology, 2021

1,398 citations recorded by the source corpus.

Parkinson’s disease is the second most common neurodegenerative disease, and its prevalence has been projected to double over the next generation. Nonetheless, an accurate diagnosis of Parkinson’s disease remains challenging, and identifying the earliest stages of the disease is a major unmet need. Recent developments include the validation of modified clinical diagnostic criteria, the introduction and testing of research criteria for prodromal Parkinson’s disease, and the identification of genetic subtypes and a growing number of genetic variants associated with Parkinson’s disease risk. There has also been significant progress in the development of diagnostic biomarkers, of which genetic and imaging tests are already part of routine work-up protocols in clinical practice, while novel tissue and fluid markers are under investigation. Parkinson’s disease is evolving from a clinical to a biomarker-supported diagnostic entity, in which an earlier identification is possible, different subtypes with diverse prognosis are recognized and novel disease-modifying treatments are in development.

View Paper: https://www.semanticscholar.org/paper/b93ee98225f7f7a810ad011c355e1743652a9d86

How researchers see this paper

The researchers whose trusted networks rank it highest, strongest advocate first. Every researcher gets a different order.

1. Zahra Naseri
2. E. Ghazizadeh
3. Hossein Rahimi
4. Zeynep Altintas
5. H. Deigner

Citations in the corpus

• Approaches of wearable and implantable biosensor towards of developing in precision medicine (2024, background): “Diagnosing PD can be challenging due to its diverse symptoms and similarities with other illnesses (88).”